Mepolizumab
Are you a clinician? See the clinical version of this page.
Given as an injection under the skin every 4 weeks. In the vasculitis EGPA it is given as three injections (300 mg) each time.
- Eosinophilic granulomatosis with polyangiitis (EGPA): 300 mg (three injections) under the skin every 4 weeks.
Tests while you take it
Watch for allergic reactions after the injection. Do not stop your other medicines unless told to.
What to know
How it is used in EGPA
Mepolizumab is used mainly for milder or relapsing EGPA, and to help keep it in remission, often so that less steroid is needed. It is not the first choice for severe, organ-threatening EGPA, where stronger medicines are used first.
Monitoring
Mepolizumab does not usually need frequent blood tests. Your team checks how your asthma, sinuses, and other symptoms respond, and watches for any reactions to the injection.
Common effects
Common effects include injection-site reactions, headache, back pain, and tiredness. Most are mild.
Important cautions
Tell your team about any allergic reaction after an injection, such as swelling, hives, or trouble breathing. Let them know if you have had shingles or a parasite infection, as these need attention before or during treatment.
What to watch for
- Signs of an allergic reaction after an injection, such as swelling of the face or throat, hives, or trouble breathing. These need urgent medical attention.
- A painful blistering rash (possible shingles), which should be assessed promptly.
- Worsening asthma or breathing symptoms, since mepolizumab is not a treatment for a sudden asthma attack.